Pineal body neoplasm
diseaseOn this page
Also known as neoplasm of pineal areaneoplasm of pineal bodyneoplasm of pineal regionneoplasm of the pineal areaneoplasm of the pineal regionpineal area neoplasmpineal area tumorpineal area tumourpineal body neoplasm (disease)pineal body tumorpineal body tumourpineal neoplasmpineal region neoplasmpineal region tumorpineal region tumourpineal tumorpineal tumourpinealomatumor of pineal areatumor of pineal body
Summary
Pineal body neoplasm (MONDO:0021232) is a cancer (an umbrella term covering 5 Mondo subtypes) and 8 clinical trials. Top therapeutic interventions include nivolumab, entinostat, and cixutumumab. A subtype of endocrine gland neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 8
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pineal body neoplasm |
| Mondo ID | MONDO:0021232 |
| NCIT | C3328 |
| UMLS | C1412004 |
| MedGen | 237252 |
| Anatomy (UBERON) | UBERON:0001905 |
| Is cancer (heuristic) | yes |
Also known as: neoplasm of pineal area · neoplasm of pineal body · neoplasm of pineal region · neoplasm of the pineal area · neoplasm of the pineal region · pineal area neoplasm · pineal area tumor · pineal area tumour · pineal body neoplasm (disease) · pineal body tumor · pineal body tumour · pineal neoplasm · pineal region neoplasm · pineal region tumor · pineal region tumour · pineal tumor · pineal tumour · pinealoma · tumor of pineal area · tumor of pineal body (+8 more)
Disease family
This is a subtype of endocrine gland neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › pineal body neoplasm
Related subtypes (13): benign endocrine neoplasm, thymus neoplasm, granulosa cell tumor, thyroid tumor, pituitary tumor, familial tumoral calcinosis, neuroendocrine neoplasm, malignant endocrine neoplasm, non-functioning endocrine neoplasm, functioning endocrine neoplasm, adrenal gland neoplasm, tumor of parathyroid gland, liver and intrahepatic bile duct neoplasm
Subtypes (5): pineal gland cancer, pineal region teratoma, pineal region meningioma, papillary tumor of the pineal region, pineal parenchymal cell neoplasm
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 8.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 3 |
| Not specified | 3 |
| PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03173950 | PHASE2 | COMPLETED | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers |
| NCT04541082 | PHASE1 | RECRUITING | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms |
| NCT01182883 | PHASE1 | WITHDRAWN | A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors |
| NCT02780804 | PHASE1 | COMPLETED | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors |
| NCT03885258 | EARLY_PHASE1 | COMPLETED | Melatonin Replacement Therapy in Pinealectomized Patients |
| NCT05259605 | Not specified | RECRUITING | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification |
| NCT06516471 | Not specified | NOT_YET_RECRUITING | The Evolution of Neuroendoscopy Guided by Head-mounted Mixed Reality Technique Navigation System in Neurosurgery |
| NCT01251913 | Not specified | TERMINATED | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NIVOLUMAB | 4 | 1 |
| ENTINOSTAT | 3 | 1 |
| CIXUTUMUMAB | 2 | 1 |
| ONC-206 | 1 | 1 |
Related Atlas pages
- Drugs: Nivolumab, Entinostat